Drug Production Facilities – An Overlooked Discharge Source for Pharmaceuticals to the Environment

  • D. G. J. Larsson


Salicylic Acid Chemical Oxygen Demand Active Pharmaceutical Ingredient Sales Price Pharmaceutical Residue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. AUE (2004) Amt für Umwelt und Energie Basel Stadt, Jahresbericht 2003 ( Scholar
  2. Bisaraya SC, Patil DM (1993) Determination of salicylic acid and phenol (ppm level) in effluent from aspirin plant. Research and Industry 38:170–172Google Scholar
  3. China Daily (2007) Google Scholar
  4. CPA (2006). Competition in the World APIs Market. Chemical Pharmaceutical Generic Association, Milan, ItalyGoogle Scholar
  5. Cui CW, Ji SL, Ren HY (2006) Determination of steroid estrogens in wastewater treatment plant of a contraceptives producing factory. Environ Monitor Assess 121:409–419CrossRefGoogle Scholar
  6. EMEA (2006) Guideline on the environmental risk assessment of medicinal products for human use. European Medicines Agency, London (CHMP/SWP/4447/00)Google Scholar
  7. Green J/US Department of Commerce (2006). Global pharmaceutical and API markets overview. Presentation at the US Pharmacopeia and Pharmaceutical Research Consortia planning meeting, Washington, April 21stGoogle Scholar
  8. Gunnarsson L, Kristiansson E, Förlin L, Nerman O, Larsson DGJ (2007). Sensitive and robust gene expression changes in fish exposed to estrogen: a microarray approach. BMC Genomics 8:149CrossRefGoogle Scholar
  9. Kidd KA, Blanchfield PJ, Mills KH, Palace VP, Evans RE, Lazorchak JM, Flick RW (2007) Collapse of a fish population after exposure to a synthetic estrogen. PNAS 104:8897–8901CrossRefGoogle Scholar
  10. Larsson DGJ, De Pedro C, Paxéus N (2007) Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mat 148:751–755CrossRefGoogle Scholar
  11. Networth Stockbroking Ltd (2005) Riding the ciprofloxacin wave. Theme report July 5th ( Data/393.pdf)Google Scholar
  12. Örn S, Holbech H, Madsen HT, Norrgren L, Petersen IG (2003) Gonad development and vitellogenin production in zebrafish (Danio rerio) exposed to ethinylestradiol and methyltestosterone. Aquat Toxicol 65:397–411Google Scholar
  13. Parrott JL, Blunt BR (2005) Life-cycle exposure of fathead minnows (Pimephales promelas) to an ethinylestradiol concentration below 1 ng/l reduces egg fertilization success and demasculinizes males. Environ Toxicol 20:131–141CrossRefGoogle Scholar
  14. Soulet B, Tauxe A, Tarradellas J (2002) Analysis of acidic drugs in Swiss wastewaters. Intern J Environ Anal Chem 82:659–667CrossRefGoogle Scholar
  15. Stenberg I (2007) LIF vill införa globala miljökrav. Läkemedelsvärlden. Sep 20 ( zino.aspx?articleID=10963)Google Scholar
  16. USFDA (1998) Guidance for industry; environmental assessment of human drugs and biologics application. US Food and Drug Administration ( Scholar
  17. Williams RT, Cook JC (2007) Exposure to pharmaceuticals present in the environment. Drug Inf J 41:133–141Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • D. G. J. Larsson
    • 1
  1. 1.Institute of Neurosciences and Physiology the Sahlgrenska Academy at the University of GothenburgGothenburgSweden

Personalised recommendations